Exhibit 99.1
For Immediate Release
Contact: Gene Cassis, Vice President of Investor Relations, 508-482-2349
Waters Corporation First Quarter 2003 Sales Up 2% Before Currency Effects,
Earnings Per Diluted Share In Line with Company's Expectations
Milford, Massachusetts, April 22, 2003 -- Waters Corporation (NYSE/WAT) reported
today first quarter 2003 sales of $221 million, an increase of 10% over the $200
million in sales reported for the first quarter of 2002. This growth is
comprised of 2% organic growth (prior to currency effects) and an 8% benefit
from foreign exchange in the quarter. Earnings per diluted share (E.P.S.) for
the first quarter were $0.26 compared to $0.26 for the comparable period in
2002. On a pro-forma basis, excluding unusual charges, E.P.S. were $0.30 for the
quarter, an increase of 11% over the pro-forma E.P.S. of $0.27 reported for the
first quarter of 2002. Free cash flow for the first quarter was approximately
$30 million.
Commenting on the quarter Douglas Berthiaume, Chairman, President and Chief
Executive Officer said, "Overall our results reflect cautious spending by our
pharmaceutical and life science customers and relatively stronger demand from
our industrial customers. Sales growth by product line for the quarter was in
line with our expectations. Additionally, we are pleased to report on the
accelerated completion of our $200 million stock buy-back program and the
successful integration of the recently acquired rheometry instrument product
line within our TA Instruments division.
Lastly, at this year's ASMS conference in June, we plan to introduce a new
triple quadrupole mass spectrometry system designed to meet the performance
requirements of researchers in drug development. Our production plan anticipates
shipments in late 2003."
The Company reported certain unusual charges in the first quarter, as explained
in the accompanying financial schedules. These consisted of restructuring
charges associated with the combination of the Company's field organizations,
the divestiture of the Company's inorganic mass spectrometry business, the
acquisition of the rheometry product line from Rheometrics Scientific Inc. and
charges related to on-going legal matters.
In addition to the results presented in accordance with Generally Accepted
Accounting Principles (GAAP), the Company believes it is appropriate to provide
"pro-forma" information that adjusts results to exclude unusual items such as
non-operational, non-cash charges and benefits, and one-time charges. Management
uses such pro-forma information internally to evaluate the Company's performance
and to manage its operations. The accompanying financial schedules contain a
detailed presentation of both GAAP and pro-forma results for the first quarter
ended March 31, 2003.
As communicated in a prior press release, Waters Corporation will webcast its
first quarter 2003 financial results conference call this morning, April 22,
2003, at 8:30 a.m. eastern time. To listen to the call, connect to
www.waters.info , choose Investor Relations and click on the Live Webcast. A
replay of the call will be available from today through April 28, 2003,
similarly by webcast, and also by phone at 402-530-7669.
Waters Corporation holds worldwide leading positions in three complementary
analytical technologies - high performance liquid chromatography (HPLC), mass
spectrometry (MS) and thermal analysis (TA). These markets account for $4.4
billion of the overall $20 billion analytical instrument market.
CAUTIONARY STATEMENT
This release contains "forward-looking" statements regarding future results and
events, including statements regarding expected financial results, future growth
and customer demand that involve a number of risks and uncertainties. For this
purpose, any statements contained herein that are not statements of historical
fact may be deemed forward looking statements. Without limiting the foregoing,
the words, "believes", "anticipates", "plans", "expects", "intends", "appears",
"estimates", "projects", and similar expressions are intended to identify
forward looking statements. The Company's actual future results may differ
significantly from the results discussed in the forward-looking statements
within this release for a variety of reasons including and without limitation:
loss of market share through competition, introduction of competing products by
other companies, pressures on prices from competitors and/or customers,
regulatory obstacles to new product introductions, lack of acceptance of new
products, changes in the demands of the Company's healthcare and pharmaceutical
company customers, changes in the healthcare market and the pharmaceutical
industry, changes in distribution of the Company's products, the short-term
effect on sales and expenses as a result of the formerly announced combination
of the Waters and Micromass sales, service and distribution organizations, and
foreign exchange fluctuations. Such factors and others are discussed more fully
in the section entitled "Risk Factors" of the Company's Form 10-K for the year
ended December 31, 2002, as filed with the Securities and Exchange Commission,
which "Risk Factors" discussion is incorporated by reference in this press
release. The forward-looking statements included in this press release represent
the Company's estimates as of the date of this press release and should not be
relied upon as representing the Company's estimates or views as of any date
subsequent to the date of this press release. The Company specifically disclaims
any obligation to update these forward-looking statements in the future.
Waters Corporation and Subsidiaries
Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)
Three Months Ended
March 31
---------------------
2003 2002
------- -------
Net sales 220,999 200,341
Cost of sales 94,211 84,634
Gross profit 126,788 115,707
Selling, general and administrative expenses 61,611 55,716
Research and development expenses 13,560 12,280
Purchased technology amortization 1,028 915
Litigation provisions (A) 1,500 2,800
Loss on disposal of business (B) 5,031 -
Restructuring and other unusual charges (C) 1,214 -
Operating income 42,844 43,996
Interest income, net 825 1,378
Income from operations before income taxes 43,669 45,374
Provision for income taxes 9,692 10,324
Income before cumulative effect of change in accounting principle 33,977 35,050
Cumulative effect of change in accounting principle, net of tax (D) - (4,506)
Net income 33,977 30,544
Income per basic common share:
Net income before cumulative effect of accounting
principle change 0.27 0.27
Cumulative effect of change in accounting principle (D) - (0.03)
Net income 0.27 0.23
Income per diluted common share:
Net income before cumulative effect of accounting
principle change 0.26 0.26
Cumulative effect of change in accounting principle (D) - (0.03)
Net income 0.26 0.22
Weighted average number of basic common shares 126,308 131,029
Weighted average number of diluted common shares
and equivalents 130,785 137,188
(A) Includes a $1.2 million provision for an ongoing environmental matter with
the Commonwealth of Massachusetts.
(B) Loss on disposal of the inorganic mass spectrometry product line.
(C) Includes restructuring and other incremental costs incurred in relation to
the Company's reorganization of the HPLC and mass spectrometry businesses,
and restructuring charges relating to the acquisition of the rheology
business of Rheometric Scientific, Inc.
(D) Effect at January 1, 2002 of a change in accounting method for patent
related costs.
Waters Corporation and Subsidiaries
Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)
Three Months Ended
March 31
------------------
2003 2002
-------- --------
Reconciliation of income per diluted share, in accordance with generally
accepted accounting principles, with pro-forma results:
Income per diluted share before cumulative effect of change in
accounting principle 0.26 0.26
-------- --------
Adjustment for litigation provisions, net of tax 1,155 2,044
Income per diluted share effect 0.01 0.01
-------- --------
Adjustment for restructuring and other unusual charges, net of tax 935 -
Income per diluted share effect 0.01 -
-------- --------
Loss on disposal of business, net of tax 3,522 -
Income per diluted share effect 0.03 -
-------- --------
Pro-forma income per diluted share: 0.30 0.27
======== ========
The pro-forma income per diluted share presented above is used by the management
of the Company to measure operating performance with prior periods and is not in
accordance with generally accepted accounting principles (GAAP). The above
reconciliation identifies those items management has excluded as non-operational
activities or transactions. Management feels these transactions are not
indicative of understanding the ongoing operations of the business or its future
outlook.
Waters Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(In thousands and unaudited)
March 31, 2003 December 31, 2002
-------------- -----------------
Cash and cash equivalents 271,572 263,312
Restricted cash 48,997 49,944
Accounts receivable 197,489 196,273
Inventories 124,853 126,920
Other current assets 15,309 13,341
Total current assets 658,220 649,790
Property, plant and equipment, net 104,517 103,650
Other assets 276,604 255,478
Total assets 1,039,341 1,008,918
Notes payable and debt 96,057 2,665
Accounts payable and accrued expenses 319,038 315,521
Total current liabilities 415,095 318,186
Other long-term liabilities 24,855 25,422
Total liabilities 439,950 343,608
Total equity 599,391 665,310
Total liabilities and equity 1,039,341 1,008,918